AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03597555
Drug: Sodium Oxybate Oral Solution 500 MG/ML
DrugBank: Sodium oxybate (DB09072)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal
Trial: NCT00006457
Drug: oltipraz
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00910741
Drug: Nanoplatin (NC-6004) and Gemcitabine
RxNorm normalized name: NC-6004 nanoplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00768677
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02200575
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05052008
Drug: Erenumab
RxNorm normalized name: ERENUMAB
DrugBank: Erenumab (DB14039)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erenumab is monoclonal antibody used for management of migraine
Trial: NCT02213107
Drug: Enzalutamide and Dutasteride or finasteride
RxNorm normalized name: tamsulosin and dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily
Trial: NCT01848002
Drug: catridecacog
RxNorm normalized name: Catridecacog
DrugBank: Catridecacog (DB09310)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
Trial: NCT00344227
Drug: Lucentis (Ranibizumab)
RxNorm normalized name: ranibizumab Injection [Lucentis]
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03303079
Drug: TEV-48125 or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
Trial: NCT01174927
Drug: diacetylmorphine (DAM)
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
Trial: NCT01853800
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01584388
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
Trial: NCT00285675
Drug: DN-101 (calcitriol) - Drug
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02580552
Drug: Cobomarsen
RxNorm normalized name: Cobomarsen
DrugBank: Cobomarsen (DB14931)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03415269
Drug: Ambroxol Hydrochloride
RxNorm normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single lozenge of 20mg ambroxol
Trial: NCT00106561
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03447145
Drug: TQ-B3203
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalation, 2/4/6/10/14/18mg/m2
Trial: NCT01566825
Drug: Amitriptyline
RxNorm normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
Trial: NCT01371682
Drug: Ropinirole XL
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
Trial: NCT03052673
Drug: ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
Trial: NCT00235313
Drug: nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: normal following with a nicotine patch
Trial: NCT00143143
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01906164
Drug: ALS-008176
RxNorm normalized name: ALS-008176
DrugBank: Lumicitabine (DB14808)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02865187
Drug: Hormonal contraception
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal contraceptives
Trial: NCT02826551
Drug: Marcaine
RxNorm normalized name: Marcaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
Trial: NCT02826551
Drug: Percocet
RxNorm normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01109381
Drug: GT08
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
Trial: NCT01272856
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 125 mg pre-filled syringe for sub-q injection weekly.
Trial: NCT01467804
Drug: Sertraline plus placebo of JWXYJN
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
Trial: NCT01467804
Drug: JWXYJN plus placebo of Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JWXYJN 3.6g/d plus placebo of sertraline
Trial: NCT00729807
Drug: pentamidine
RxNorm normalized name: Pentamidine
DrugBank: Pentamidine (DB00738)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004785
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004785
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01457430
Drug: Icatibant
RxNorm normalized name: Icatibant
DrugBank: Icatibant (DB06196)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 mg subcutaneous dose of Icatibant
Trial: NCT01765881
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
Trial: NCT01663987
Drug: tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 18 mcg once a day (QD)
Trial: NCT00401115
Drug: MS-R001 (rapamycin)
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection in various dosages
Trial: NCT00401115
Drug: MS-R001 (rapamycin)
RxNorm normalized name: MS-1819
DrugBank: MS-1819 (DB15004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular injection in various dosages
Trial: NCT02006654
Drug: Idalopirdine
RxNorm normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, encapsulated tablets, orally
Trial: NCT00890318
Drug: ABT-072
RxNorm normalized name: ABT-072
DrugBank: ABT-072 (DB15156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
Trial: NCT02487485
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: . Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions-once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
Trial: NCT02487485
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
Trial: NCT01370538
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Trial: NCT00819195
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg daily subcutaneous injection. Six-month duration.
Trial: NCT01122953
Drug: Epamin
RxNorm normalized name: Epaminurad
DrugBank: Epaminurad (DB18973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
Trial: NCT03135795
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients received intravenous dexmedetomidine 1μg/Kg for induction.
Trial: NCT03135795
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.
Trial: NCT03135795
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received intravenous rocuronium 0.6mg/Kg for induction.
Trial: NCT03135795
Drug: sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received inhalation of sevoflurane (1-2%) for maintenance.
Trial: NCT03135795
Drug: Parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40mg was given single intravenously before incision.
Trial: NCT00849472
Drug: paclitaxel + pazopanib
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 cycles of paclitaxel + pazopanib
Trial: NCT00849472
Drug: pazopanib monotherapy
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6 months of treatment with pazopanib monotherapy
Trial: NCT00907114
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
Trial: NCT00907114
Drug: Polivynilic alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
Trial: NCT04041128
Drug: Lynparza
RxNorm normalized name: Lynparza
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lynparza taken orally at a dose of 300mg twice daily for 7 days
Trial: NCT00309244
Drug: 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
Trial: NCT00902967
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg, once a day dosing at night after meals
Trial: NCT02221414
Drug: Linagliptin/Metformin FDC
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02221414
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02221414
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00696592
Drug: Bevacizumab (Avastin), Verteporfin (Visudyne)
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01320449
Drug: recombinant human erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
Trial: NCT03601052
Drug: Remlarsen
RxNorm normalized name: Remlarsen
DrugBank: Remlarsen (DB19131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection at site of one excisional wound
Trial: NCT02663440
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide
Trial: NCT01990781
Drug: LD: Lidocaine and dexamethasone
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
Trial: NCT01990781
Drug: L:Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
Trial: NCT01990781
Drug: D: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: D:intravenous dexamethasone 8 mg before induction of anesthesia
Trial: NCT00286455
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
Trial: NCT00286455
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
Trial: NCT02487199
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Trial: NCT02487199
Drug: ombitasvir/paritaprevir/ritonavir
RxNorm normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir
Trial: NCT03827642
Drug: Treatment A: Naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received naloxone nasal spray following a 10 hour fast.
Trial: NCT03827642
Drug: Treatment B: Naloxone Nasal Spray
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received naloxone nasal spray following a 10 hour fast.
Trial: NCT03827642
Drug: Treatment C: Naloxone HCl Intravenous (IV) Injection
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received naloxone HCl IV injection following a 10 hour fast.
Trial: NCT03827642
Drug: Treatment D: Naloxone HCl Intramuscular (IM) Injection
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received naloxone HCl IM injection following a 10 hour fast.
Trial: NCT01363076
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IN dose of 15 mg ketorolac tromethamine for subjects weighing \<50 kg.
Trial: NCT01363076
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
Trial: NCT04220281
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol infusion during surgery
Trial: NCT04220281
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitroglycerin infusion during surgery
Trial: NCT01373229
Drug: Lenalidomide + Plerixafor (+ Rituximab)
RxNorm normalized name: Plerixafor
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~2. Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~3. Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) \<100.0 x 109 / L.~4. Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~   * Cohort 1: 0.24 mg/kg~  * Cohort 2: 0.32 mg/kg~  * Cohort 3: 0.42 mg/kg~  * Cohort 4: 0.54 mg/kg~5. Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~6. Subjects will then continue single agent lenalidomide until disease progression.
Trial: NCT00084253
Drug: Atazanavir/ Stavidine / Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
Trial: NCT00084253
Drug: Atazanavir-Ritonavir/ Stavidine / Lamivudine
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD\*, Once daily, 96 weeks.
Trial: NCT04095013
Drug: Bupivacaine, fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
Trial: NCT04095013
Drug: Bupivacaine, dexmedetomidine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
Trial: NCT00890162
Drug: Omalizumab (Xolair)
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01312129
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
Trial: NCT00461968
Drug: Ezetimibe and Simvastatin
RxNorm normalized name: Ezetimibe and Simvastatin Tablets
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03720847
Drug: Oral Micronized Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
Trial: NCT00884949
Drug: BMN 110
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~* Weeks 1-12: 0.1 mg/kg/week~* Weeks 13-24: 1.0 mg/kg/week~* Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week.
Trial: NCT03600129
Drug: 30 milliliters of 0.375% Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
Trial: NCT01567085
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03530228
Drug: Tegoprazan (C1)
RxNorm normalized name: C1-INH
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan QD, oral administration. Treatment A
Trial: NCT03530228
Drug: Tegoprazan (C1)
RxNorm normalized name: C1-INH
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan QD, oral administration. Treatment B
Trial: NCT03530228
Drug: Treatment C: Tegoprazan (C1)
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan BID, oral administration